Lunit & Labcorp Partner to Expand AI-Powered Digital Pathology Research

The collaboration will accelerate the validation and development of AI-powered diagnostic models by combining Lunit’s AI pathology technologies with Labcorp’s research infrastructure.

Lunit and Labcorp have announced a strategic collaboration designed to accelerate AI-powered digital pathology research and strengthen the development of advanced diagnostic tools for cancer detection.

The companies said the partnership brings together Lunit’s portfolio of AI pathology technologies with Labcorp’s large-scale diagnostic and research capabilities, enabling broader adoption of digital pathology solutions.

Lunit is a global medical AI company known for developing AI solutions for cancer detection and digital pathology, with deployments across hospitals and research centers worldwide.

Labcorp, on the other hand, is a leading global life sciences and diagnostics company, based at Burlington, North Carolina, offering extensive clinical laboratory services, oncology research platforms, and one of the industry's largest test development infrastructures.

The collaboration is expected to support research aimed at improving diagnostic accuracy, workflow efficiency, and scalability in laboratories transitioning from traditional microscope-based assessment to AI-enabled Digital Pathology.

Both organizations said the goal is to reduce bottlenecks in pathology workflows, enhance cancer detection capabilities, and help clinical teams access more precise diagnostic insights.

According to Lunit, its AI technology has been developed to support pathologists in identifying, classifying and analyzing cancer patterns through digital slide imaging. The company mentioned these models are designed to enhance diagnostic precision and reduce manual workload in high-volume pathology settings.

By bringing these AI capabilities together with Labcorp’s research infrastructure, the partnership aims to build a stronger validation pathway and speed up the deployment of AI-powered diagnostic models across a broad range of pathology applications, from cancer detection to biomarker analysis.

Further, the diagnostic company noted that combining its clinical research footprint with Lunit’s AI systems will strengthen efforts to develop next-generation digital pathology pipelines that can support oncology research, biomarker development, and future clinical diagnostic offerings.

As per reports, the partnership is also intended to expand the availability of AI-assisted pathology tools across more laboratories and institutions.

Stay tuned for more such updates on Digital Health News